ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02768389
Recruitment Status : Recruiting
First Posted : May 11, 2016
Last Update Posted : September 24, 2018
Sponsor:
Collaborators:
University of Cincinnati
OhioHealth Research Institute
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Brief Summary:

Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab. This research study involves bevacizumab in combination with a special diet called the Modified Atkins Diet (MAD).

The purpose of this study is to research if patients can stay on the MAD when it is added to the standard bevacizumab treatment.


Condition or disease Intervention/treatment Phase
Glioblastoma Brain Tumor Drug: Bevacizumab Behavioral: Modified Atkins Diet Early Phase 1

Detailed Description:

Primary Objective

- Determine compliance to treatment at 6 and 12 weeks. Compliance is assessed by review of the daily food diary and the urine and serum ketone levels. Diet compliance is defined as following the diet guidelines 80% of the time with resultant ketosis 80% of the time. If 60% of the patients are compliant with the diet, as defined above, that is a considered a positive result.

Secondary Objective(s)

  • Determine patient compliance in monitoring of blood glucose and urine levels of ketosis.
  • Determine obstacles to compliance.
  • Determine the frequency of achieving ketosis, as measured by urine ketones checked daily and serum BHB checked every two weeks.
  • Determine quality of life (FACT-BR) and adverse events.
  • Determine response, progression free survival at 6 months (PFS 6), and overall survival (OS).

Exploratory Objective

  • To correlate levels of ketosis and blood sugar with treatment outcome.
  • To correlate the level of MCT4 expression and IDH1 mutation status with treatment outcome.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
Actual Study Start Date : September 6, 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Modified Atkins Diet and Bevacizumab
Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
Drug: Bevacizumab
Subjects receive Bevacizumab as standard of care

Behavioral: Modified Atkins Diet
The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (< 20gm/day).
Other Name: MAD




Primary Outcome Measures :
  1. Number of subjects following Modified Atkins Diet [ Time Frame: Up to 12 weeks ]
    The number of patients following a Modified Atkins Diet for at least 80% of the time as a measure of feasibility

  2. Number of subjects with ketosis [ Time Frame: Up to 12 weeks ]
    The number of patients with documented ketosis (Serum beta-hydroxybutyrate (BHB) above 4mg/L) for at least 80% of the time as a measure of feasibility


Secondary Outcome Measures :
  1. Correlation of blood sugar levels by compliance level [ Time Frame: Up to 12 weeks ]
    Correlate the relationship between blood sugar levels and measured level of compliance

  2. Correlation of ketosis values by compliance level [ Time Frame: Up to 12 weeks ]
    Correlate the relationship between ketosis values and measured level of compliance

  3. Correlation of ketosis values by tumor response [ Time Frame: Up to 12 weeks ]
    Correlate the relationship between ketosis values and measured level of tumor response as a measure of treatment outcomes

  4. Correlation of blood sugar levels by tumor response [ Time Frame: Up to 12 weeks ]
    Correlate the relationship between blood sugar levels and measured level of tumor response as a measure of treatment outcomes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external beam fractionated radiotherapy and temozolomide chemotherapy.
  • Any number of prior recurrences are allowed
  • Karnofsky Performance status ≥60
  • Patients must have normal organ and marrow function as defined below:

    • Hemoglobin ≥ 9.0 g/dl
    • Absolute neutrophil count ≥ 1.5 x 10^9/L
    • Platelet count ≥ 100 x 10^9/L
    • Total bilirubin ≤ 1.5 X institutional upper limit of normal
    • Aspartate aminotransferase (AST) (SGOT) ≤ 3.0x institutional upper limit of normal
    • Alanine aminotransferase (ALT) (SGPT) ≤ 3.0x institutional upper limit of normal
    • Serum Creatinine ≤ 1.5 X institutional upper limit of normal

      • Cr <2, blood urea nitrogen (BUN) < 100mg/dL
    • Blood coagulation parameters: international normalized ratio (INR) ≤ 1.5
  • Minimum interval since last drug therapy;

    • 3 weeks since last non-cytotoxic therapy
    • 3 weeks must have elapsed since the completion of non-nitrosourea-containing chemotherapy regimen.
    • 6 weeks since the completion of a non-nitrosourea-containing therapy regimen.
  • Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treatment stage I or II cancer from which the patient is in complete remission. Patients with other malignancies must also be disease free for at least three years.
  • Patients must be maintained on a stable corticosteroid regimen from the time of their baseline scan until the start of the treatment and/or for at least 5 days before starting treatment.
  • Patients with the potential for pregnancy or impregnating their partners must agree to follow acceptable birth control methods to avoid conception. The effects of bevacizumab on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence prior to study entry, for the duration of study participation and after completing treatment. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately.
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Patients who are receiving any other investigational agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab.
  • Patients who have had previous treatment with bevacizumab.
  • Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, active bowel instruction, diabetic (insulin dependent), Active or remote pancreatitis, Pancreatic insufficiency, symptomatic congestive heart failure (NYHA > 2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breastfeeding women are excluded from this study because bevacizumab is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with bevacizumab, breastfeeding should be discontinued if the mother is treated with bevacizumab. These potential risks may also apply to other agents used in this study.
  • Known diagnosis of human immunodeficiency virus (HIV). (HIV testing is not required).
  • Patients who have undergone major surgery (ie, intra-thoracic, intra abdominal or inra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ≤ 1 week prior to starting study drug, or who have not recovered from side effects of previous procedure or injury.
  • Patients with cirrhosis, or active viral or nonviral hepatitis.
  • Implanted pacemaker, defibrillator, deep brain stimulator, or other implanted electronic devices in the brain or other documented clinically significant arrhythmias.
  • Evidence of increased intracranial pressure (clinically significant papilledema, vomiting, and nausea, or reduced level of consciousness).
  • Patients who are unwilling to comply with protocol.
  • Myocardial infarction within the last 6 months.
  • Symptomatic atrial fibrillation.
  • Patients with a body mass index (BMI) >35, < 20.
  • Patients with a genetic disorder of fat metabolism.
  • Patients who are allergic to milk.
  • Insulin dependent diabetes mellitus.
  • Patients with uncontrolled hypertension. Patients with a history of hypertension must be well controlled (<160/90) on a regimen of hypertensive medication.
  • Patients with known inborn errors of metabolism of primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects, pyruvate carboxylase deficiency and porphyria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02768389


Contacts
Contact: Lisa Rogers, DO 216-844-3717 Lisa.Rogers1@uhhospitals.org

Locations
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45220
Contact: Rekha Chaudhary, MD    513-558-2199    tripatrr@ucmail.uc.edu   
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Lisa Rogers, DO    216-844-3717    Lisa.Rogers1@uhhospitals.org   
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive cancer Center Recruiting
Cleveland, Ohio, United States, 44195
Contact: David Peereboom, MD    216-445-6068    peerebd@ccf.org   
OhioHealth Research and Innovation Institute Recruiting
Columbus, Ohio, United States, 43214
Contact: Mohamed Hamza, MD    614-566-1250    mohamed.hamza@ohiohealth.com   
Principal Investigator: Mohamed Hamza, MD         
Sponsors and Collaborators
Case Comprehensive Cancer Center
University of Cincinnati
OhioHealth Research Institute
Investigators
Principal Investigator: Lisa Rogers, DO University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT02768389     History of Changes
Other Study ID Numbers: CASE10314
First Posted: May 11, 2016    Key Record Dates
Last Update Posted: September 24, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Case Comprehensive Cancer Center:
Modified Atkins Diet
MAD
Brain Tumor
Glioblastoma

Additional relevant MeSH terms:
Glioblastoma
Brain Neoplasms
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents